Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.80 USD
Change Today -0.10 / -1.12%
Volume 16.1K
ZSAN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

zosano pharma corp (ZSAN) Snapshot

Open
$9.18
Previous Close
$8.90
Day High
$9.18
Day Low
$8.65
52 Week High
01/27/15 - $12.40
52 Week Low
03/26/15 - $8.00
Market Cap
105.0M
Average Volume 10 Days
9.9K
EPS TTM
--
Shares Outstanding
11.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOSANO PHARMA CORP (ZSAN)

Related News

No related news articles were found.

zosano pharma corp (ZSAN) Related Businessweek News

No Related Businessweek News Found

zosano pharma corp (ZSAN) Details

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company’s lead product candidates include Daily ZP-PTH, a synthetic form of parathyroid hormone for treating severe osteoporosis, which has completed a Phase II trial; ZP-Glucagon, a hormone that raises blood glucose levels, intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia, which is in Phase II clinical trial; and ZP-Triptan, a class of serotonin receptor agonists known as triptans, used for the treatment of migraine, which is in Phase I and II clinical trials. It has strategic partnership and license agreement with Eli Lilly and Company to develop ZP-PTH microneedle patch products; and Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.

26 Employees
Last Reported Date: 03/26/15
Founded in 2006

zosano pharma corp (ZSAN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.0K
Chief Operations Officer
Total Annual Compensation: $203.3K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $329.8K
Compensation as of Fiscal Year 2014.

zosano pharma corp (ZSAN) Key Developments

Zosano Pharma Corporation Announces Consolidated Unaudited Financial Results for the Year Ended December 31, 2014; to Release of Clinical Data from Both its ZP-Glucagon and ZP-Triptan Programs in 2015

Zosano Pharma Corporation announced consolidated unaudited financial results for the year ended December 31, 2014. For the year, the company reported revenue of $2,861,000 against $4,250,000 a year ago. The decrease was primarily due to the fact that contract revenue the company earned under its license and collaboration agreement with Asahi Kasei Pharma Corporation (Asahi) in 2013 did not recur in 2014. This decrease was only partially offset by license-fee revenue earned under the company's collaboration and license agreement with Novo Nordisk A/S in 2014. Loss from operations was $12,612,000 against $7,969,000 a year ago. Net loss was $14,241,000 against $5,608,000 a year ago. Net loss per basic and diluted common share was $2.78 against $1.10 a year ago. The company announced that daily ZP-PTH for osteoporosis: confirm Phase 3 clinical trial design with regulatory authorities is expected by 2015 and to establish Phase 3 clinical supply inventory is expected in fourth quarter in 2015. ZP-Glucagon for hypoglycemia: complete Phase 2 clinical trial in diabetic patients with induced hypoglycemia is expected in third quarter of 2015; ZP-Triptan for migraine in complete phase 1 clinical trial expected in 2015.

Zosano Pharma Corporation Presents at 27th Annual ROTH Conference, Mar-09-2015 10:00 AM

Zosano Pharma Corporation Presents at 27th Annual ROTH Conference, Mar-09-2015 10:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Vikram Lamba, Chief Executive Officer, President and Director.

Zosano Pharma Corporation(NasdaqGM:ZSAN) added to NASDAQ Composite Index

Zosano Pharma Corporation has been added to NASDAQ Composite Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZSAN:US $8.80 USD -0.10

ZSAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $158.99 USD -0.67
Corium International Inc $9.00 USD -0.03
FUJIFILM Holdings Corp ¥4,638 JPY -21.50
View Industry Companies
 

Industry Analysis

ZSAN

Industry Average

Valuation ZSAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOSANO PHARMA CORP, please visit www.zosanopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.